PAX3 and melanoma: Chromatin-immunoprecipitation (ChIP) for BRN2, performed on Dauv-1 melanoma cell extracts, followed by qPCR, revealed quantitative BRN2 binding to both binding sites, comparable to BRN2 binding on the PAX3 promoter (Fig. 5F–H).